Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Study Overview: Regeneron Pharmaceuticals is conducting a real-world evidence study titled Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept 2 mg: A US Real-World Evidence Study Using the IRIS Registry. The study aims to estimate the incidence of retinal vasculitis (RV) among adult patients receiving Aflibercept 2 mg in the United States, highlighting its significance in understanding potential adverse effects associated with this treatment.
Intervention/Treatment: The intervention being tested is Aflibercept 2 mg, administered intravitreally. This drug is used to treat various retinal diseases, and the study seeks to observe its safety profile concerning RV.
Study Design: This is an observational cohort study with a retrospective time perspective. It will utilize secondary data from the IRIS Registry to identify and confirm cases of RV among patients who have received Aflibercept 2 mg.
Study Timeline: The study is not yet recruiting, with an estimated start date of July 1, 2025. The study was first submitted on December 24, 2024, and its last update was on June 23, 2025. These dates are crucial as they guide the study’s progression and inform stakeholders of its current status.
Market Implications: The study’s findings could significantly impact Regeneron’s stock performance and investor sentiment, particularly if the results indicate a higher incidence of RV. This could also affect competitors in the retinal treatment market, as safety profiles are a critical factor in drug adoption.
The study is ongoing, with further details available on the ClinicalTrials portal.